Stock comparison
IDEXX Laboratories
McKesson
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
MCK
McKesson
Market cap
$91.42B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MCK | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 57C | IDXX |
| Benjamin Graham | 72B | 28F | IDXX |
| Philip Fisher | 67B | 43D | IDXX |
| Peter Lynch | 63C | 39D | IDXX |
| Joel Greenblatt | 75B | 46D | IDXX |
| Charlie Munger | 79B | 36D | IDXX |
| Terry Smith | 76B | 49D | IDXX |
Side-by-side metrics
| Metric | IDXX | MCK |
|---|---|---|
| Market cap | $42.11B | $91.42B |
| P/E (TTM) | 39.0x | 19.5x |
| EV/EBIT | 31.6x | 14.9x |
| ROIC (TTM) | 40.66% | 31.07% |
| Gross margin | 62.05% | 3.61% |
| Net margin | 24.63% | 1.18% |
| Revenue CAGR 5y | 7.56% | 11.19% |
| EPS CAGR 5y | 10.79% | 51.54% |
| Debt / Equity | 0.7x | - |
| Dividend yield | 0.0% | 0.42% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Net margin24.63%vs 1.18%+95%
- Gross margin62.05%vs 3.61%+94%
- ROIC (TTM)40.66%vs 31.07%+24%
MCK leads on
- Debt / Equity-vs 0.7x+117%
- Dividend yield0.42%vs 0.0%+100%
- EPS CAGR 5y51.54%vs 10.79%+79%
- Market cap$91.42Bvs $42.11B+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.